It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Medical information request
Medical information request

Latest Updates:  December 2022

  • Patient exposure:  Homepage
  • Key safety topics:  PML
  • Posters from ECTRIMS 2022 (COVID-19)

As of 31st August 20221

Updated man-women image
**exposure includes both clinical trials and postmarketing experience; postmarketing patient exposure is estimated based on worldwide sales volume

As of 31st August 2022, exposure to fingolimod^ (any dose) by duration from Novartis MS clinical trials1

Updated Exposure image
^Actual exposure to fingolimod (any dose) in clinical trials by duration
Click here to request fingolimod local Prescribing Information
Click here to request fingolimod local RMP educational materials
 

Report an adverse event

border
References

1. Data on File, cutoff date 31st August 2022, Novartis Pharma AG.
* Indication wording varies in different countries. The current website is a global information resource. Local Prescribing Information/ Summary of Product Characteristics approved by individual country’s regulatory authority is the primary source of information for the indication of fingolimod in the individual country.